Mark Heaney

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Renier J. Brentjens, Isabelle Rivière, Jae H. Park et al. · Blood · 2011 · 1.3K citations · Full text

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

William Kevin Kelly, Owen A. O’Connor, Lee M. Krug et al. · Journal of Clinical Oncology · 2005 · 898 citations · Full text

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease

Eli L. Diamond, Lorenzo Dagna, David M. Hyman et al. · Blood · 2014 · 579 citations · Full text

Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies

Owen A. O’Connor, Mark Heaney, Lawrence B. Schwartz et al. · Journal of Clinical Oncology · 2005 · 402 citations

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

Daniel J. DeAngelo, Richard M. Stone, Mark Heaney et al. · Blood · 2006 · 274 citations · Full text